Dicot Pharma’s rights issue oversubscribed
Uppsala, Sweden, September 4, 2024. Dicot Pharma AB (”Dicot Pharma”) today announces that the rights issue of units was subscribed to 124 percent, thus oversubscribed. The rights issue consists of shares and warrants of series 6 ("Units"), with preferential rights for existing shareholders (the "Rights Issue"). The outcome shows that 97,645,294 Units (approx. 95.5 percent of the Rights Issue) have been subscribed for with unit rights. In addition, Dicot Pharma received applications for subscription of a total of 29,206,360 Units without the support of unit rights (approx. 28.6 percent of the